Dr. Reddy’s launches OTC Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120mg extended-release tablets

Dr. Reddy’s launches OTC Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120mg extended-release tablets

Dr. Reddy’s Laboratories has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D 12 Hour Allergy & Congestion, in the U.S. market on November 18, 2014.

Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA).

The Allegra-D 12 Hour brand has U.S. sales of approximately $49.8 million for the latest 52 weeks ending October 6, 2014 for Total US Multi Outlet according to IRI.

Dr. Reddy's Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg is available in a 20 count blister.

Dr. Reddy's Laboratories (RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets.